$HIMS (-1,68 %) - CEO Andrew Dudum:

In a country where "access" depends on drug company claims, not on how many people can afford and access the drugs they need, today's FDA decision on tirzepatide is not surprising - but it should make you angry.

Our priority should be finding a solution to the obesity crisis in the U.S., rather than helping anti-competitive drug companies continue to impose extortionate prices on millions of Americans who want to take control of their own health care.

Nothing would better improve the quality of life for millions of Americans than making GLP-1 truly affordable and accessible to all who need it. Let's put America's health first, not the interests of big pharma.

More than two-thirds of American adults are overweight or obese, and one in six deaths in the U.S. is due to obesity. With the scale of our platform and the expertise of our team, we have $HIMS (-1,68 %) has the opportunity - and the responsibility - to address this public health crisis.

But not only do we provide individualized treatment options for the disease that characterizes our country, we also engage with Americans to understand how they think about their bodies, how they lose weight and the impact it has on their lives.

In our survey, 85% of respondents said that at least one aspect of their lives would improve if they lost weight. That's reason enough to make sure they have the tools they need to achieve this.